Mujdat Zeybel, MD, NIHR Nottingham Biomedical Research Centre This study demonstrated CMCS supplementation significantly decreased liver fat, improved liver function, and decreased liver inflammation in NAFLD patients, suggesting CMCS may be an effective therapeutic strategy for NAFLD, No drugs have been approved to treat NAFLD, and effective treatment options with long-term safety are urgently required. The combined metabolic cofactor supplementation (CMCS) regimen developed by the Nottingham group and used in this trial consists of: 1g nicotinamide riboside (NR), which raises mitochondrial NAD+ levels, and boosts fat metabolism 3.73g L-carnitine tartrate, which promotes transport of fat into the mitochondria 12.35g L-serine, which increases glutathione synthesis 2.55g N acetyl-L-cysteine (NAC), which also promotes glutathione production and reduces oxidative stress A total of 31 patients with MRI-confirmed non-alcoholic steatosis were randomized to either placebo (N=11) or the CMCS combination (N= 20)
10.1210/jc.2011-0555 56 IwataN.HasegawaT.FujitaS.NagaoS.NakanoY.NadaT.et al (2018)
Notably, self-employed people or those who otherwise buy health insurance using Federal or state health care exchanges are required to switch to Medicare at age 65, so this only applies to people working as employees (or to the spouses of employees) of a company that offers employer-sponsored qualifying HDHP insurance
L-carnitine lowers blood cholesterol levels, promotes increased fat metabolism during aerobic exercise (running, swimming and other breathing exercises)
